GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hemostemix HEM.V · CAD

Health Care · TSX Venture · 🇨🇦 Canada

Compare

0.05

-9.09%

Close of 6 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Hemostemix — daily TSXV:HEM Delayed
Market value
C$9.8m
Last close × shares
Volume
104.5k
Shares, 6 Nov 2026

About Hemostemix

Its shares trade on TSX Venture under the ticker HEM.V. It has been listed since 20 December 2012.

Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-12-20. The firm has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The firm holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

Figures and description from our data supplier, not checked against the company's own report.

More about Hemostemix →

Latest on Hemostemix

Our reporting

We have not reported on Hemostemix yet.

Next results

27 Nov 2026

Due on 27 Nov 2026.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Hemostemix's ticker?

Hemostemix trades as HEM.V on TSX Venture, under ISIN CA4236943060.

What was Hemostemix's last closing price?

0.05 on 6 Nov 2026. The figure is in CAD and is never converted.

When does Hemostemix next report results?

Results are expected on 27 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.